FRMD8 Inhibitors
FRMD8 Inhibitors encompass a range of compounds that influence various kinases and signaling pathways, leading to an indirect inhibition of FRMD8's functional activity. Staurosporine, for instance, is a potent kinase inhibitor with a broad spectrum of targets, including those kinases that phosphorylate FRMD8, inhibiting its activation and downstream signaling involvement. LY294002 and Wortmannin are PI3K inhibitors that by reducing PI3K activity, can lead to a decrease in the phosphorylation of downstream targets, potentially diminishing the role FRMD8 plays in PI3K-related signaling pathways. The suppression of these kinases can lead to a decreased functional activity of FRMD8 by reducing the phosphorylation events that are essential for its signaling roles.
In the MAPK/ERK pathway, inhibitors like U0126 and PD98059 block the activation of MEK1/2 and ERK, respectively. Such inhibition can be critical if FRMD8's function or the function of its interacting partners relies on this pathway for activation through phosphorylation. Inhibitors targeting other kinases, such as SB203580 and SP600125, which selectively inhibit p38 MAPK and JNK respectively, could reduce phosphorylation of substrates that either interact with or regulate FRMD8, leading to an indirect inhibition of its activity. Similarly, Rapamycin suppresses mTORC1, which could downregulate the synthesis of proteins involved in FRMD8's functional pathways, while PP2, Dasatinib, Gefitinib, and Sorafenib target specific kinases like Src family kinases, BCR-ABL, EGFR, and RAF kinases respectively.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
A potent kinase inhibitor that targets a broad range of kinases, which can disrupt signaling cascades that phosphorylate FRMD8, thereby inhibiting its activation and subsequent signaling functions. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A phosphoinositide 3-kinases (PI3K) inhibitor that by suppressing PI3K activity can lead to reduced phosphorylation of downstream targets, potentially decreasing FRMD8's role in PI3K-related signaling pathways. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A selective inhibitor of p38 MAPK which through inhibition of this kinase could reduce the phosphorylation of substrates involved with FRMD8 function, indirectly leading to decreased FRMD8 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor which by inhibiting mTORC1 can downregulate protein synthesis and other processes that may be necessary for FRMD8 function or expression, resulting in its decreased activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Another PI3K inhibitor that by inhibiting PI3K can diminish the kinase activity that would otherwise contribute to FRMD8-mediated signaling, leading to a reduction in FRMD8 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK) that could prevent JNK-mediated phosphorylation of proteins that interact with or regulate FRMD8, thereby indirectly inhibiting FRMD8 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
A MEK inhibitor that blocks ERK activation, which may be necessary for the phosphorylation and activation of FRMD8 or proteins that regulate FRMD8, leading to reduced FRMD8 activity. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
A Src family kinase inhibitor that can prevent the activation of Src kinases, potentially affecting FRMD8 function if FRMD8 is downstream of or regulated by Src kinase signaling. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
A tyrosine kinase inhibitor that by inhibiting BCR-ABL and Src family kinases could reduce the phosphorylation of FRMD8 or its associated proteins, leading to decreased activity of FRMD8. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
An EGFR tyrosine kinase inhibitor that can prevent EGFR-mediated signaling pathways, which may indirectly reduce FRMD8 activation or its role in EGFR-related signaling processes. | ||||||